MedTrace Logo

Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.

NCT05669417 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2024-08-28

No results posted yet for this study

Summary

Post-operative atrial fibrillation (POAF) is commonly observed in patients post cardiac surgery without a previous history of atrial fibrillation (AF) or other arrythmias. It's associated with significant postoperative complications including infection, bleeding reoperation, increased hospital length of stay (LOHS) and mortality. Magnesium has been identified as a potentially interesting compound with easy access and low toxicity. Hypomagnesemia has been observed frequently immediately after cardiac surgery. Both reduction of abnormal atomicity of atrial myocardium and prolongation of the atrial refractory period caused by administration of magnesium may prevent AF. The POMPAE trial will analyse the effectiveness of MgSO4 versus placebo (double blind randomized trial) in the prevention of POAF after cardiac surgery.

Conditions

  • Atrial Fibrillation New Onset

Interventions

DRUG

Magnesium sulfate

Based on serum levels, bolus and or continuous administration is provided as dictated by study protocol.

Sponsors & Collaborators

  • HagaZiekenhuis

    lead OTHER

Principal Investigators

  • Jeroen Ludikhuize, MD, PhD · Medical specialist

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-07-17
Completion
2023-08-06

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05669417 on ClinicalTrials.gov